MHE Week in Review - HIV

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the potential for extended dosing intervals.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded those from the twice-yearly dosing.

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, according to new research published in Health Science Reports.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.

The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.

Positive HIV status as well as socioeconomic disadvantages, not breastfeeding, are associated with infant length and birth weight, according to the results of a new South African study.